Novo Nordisk will apply Dicerna Pharmaceuticals’ GalXC™ platform to discover and develop RNA interference (RNAi) therapies for liver-related cardio-metabolic diseases, including chronic liver diseases, nonalcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and unspecified rare diseases . . .
Home Metabolic Disorders Diabetes Dicerna, Novo Nordisk Eye 30+ Liver Targets in Up-to-$3.8B RNAi Partnership

- Metabolic Disorders
- Diabetes
- Drug Discovery
- RNA
- RNAi
- OMICs
- GEN Edge
- News
- Industry News
- Liver Diseases
- Rare and Neglected Diseases
Dicerna, Novo Nordisk Eye 30+ Liver Targets in Up-to-$3.8B RNAi Partnership
Novo Nordisk will apply Dicerna Pharmaceuticals’ GalXC™ platform to discover and develop RNA interference (RNAi) therapies for liver-related cardio-metabolic diseases, including chronic liver diseases, nonalcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and unspecified rare diseases, through a collaboration that could generate more than $3.8 billion for Dicerna. [NIH]